Kalaris Therapeutics, Inc. — Income Charts
3 quarters of history · ending 2019-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D
$7M
D&A
—
Operating Income
$-8M
EBITDA
$-8M
Interest Expense
—
Interest Income
$665K
Other Income/Expense
—
Pretax Income
—
Tax Provision
—
Net Income
$-7M
Operating Margin
-3603.0%
Net Margin
-3213.3%
Effective Tax Rate
—
ETR (Continuing Operations)
—
ETR Federal Statutory
21.0%
ETR State + Local (pp)
2.4%
ETR Foreign Differential (pp)
—
Operating Lease Cost
$1M
Income YoY Variation
—
Revenue QoQ Variation
-100.0%
Income QoQ Variation
-42.6%